参考资料（上下滑动查看全部）：

[1]ANALYSIS TREATMENT OUTCOME OF 46 REFRACTORY/RELAPSED PEDIATRIC MATURE B CELL LYMPHOMA PATIENTS-MULTI-CENTER EXPERIENCE FROM CHINA. ICML 2023 Nr.32

[2]Liu, Y., Deng, B., Hu, B., Zhang, W., Zhu, Q., Liu, Y., Wang, S., Zhang, P., Yang, Y., Yang, J., Zheng, Q., Yu, X., Gao, Z., Zhou, C., Han, W., Yang, J., Jin, L., Tong, C., Chang, A. H., & Zhang, Y. (2022). Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma. Blood advances, 6(3), 717–730. https://doi.org/10.1182/bloodadvances.2021004557.

[3]IMPACT OF ARID1A AND TP53 MUTATIONS IN PEDIATRIC REFRACTORY OR RELAPSED MATURE B-CELL LYMPHOMA TREATED WITH CAR-T CELL THERAPY. EHA 2023 P1231

[4]Li, Y., Liu, Y., Yang, K., Jin, L., Yang, J., Huang, S., Liu, Y., Hu, B., Liu, R., Liu, W., Liu, A., Zheng, Q., & Zhang, Y. (2023). Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy. Cancer cell international, 23(1), 281. https://doi.org/10.1186/s12935-023-03122-2

[5]LANDSCAPE OF DRIVER MUTATIONS AND THEIR CLINICAL IMPACTS IN CHINESE PEDIATRIC PATIENTS WITH MATURE B-CELL NON-HODGKIN'S LYMPHOMA AND T-CELL LYMPHOBLASTIC LYMPHOMA . ICML 2023 Nr.35

[6]Clinical Pathology Characteristics of 221 Pediatric Anaplastic Large Cell Lymphoma-3 Years Follow up and Experience from China Net Childhood Lymphoma(CNCL). ASH 2023 P4489

[7]Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma. ASH 2023 P1709

[8]Prognostic Impact of Minimal Disseminated Disease(MDD) and Minimal Residual Disease(MRD) in Chinese Pediatric Patients with ALK-K-Positive Anaplastic Large Cell Lymphoma(ALCL). ASH 2023